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Sheelan S Rajab1 and Shahla K Alalaf2*Abstract
Background: The third stage of labour may be complicated by retained placenta, which should be managed
promptly because it may cause severe bleeding and infection, with a potentially fatal outcome. This study
evaluated the effectiveness of umbilical vein injection of misoprostol for the treatment of retained placenta in a
hospital setting.
Methods: This hospital-based placebo-controlled trial was conducted at the Maternity Teaching Hospital, Erbil City,
Kurdistan region, Northern Iraq from April 2011 to February 2012. The inclusion criteria were: gestational age of at
least 28 weeks, vaginal delivery, and failure of the placenta to separate within 30 minutes after delivery of the infant
despite active management of the third stage of labour. Forty-six women with retained placentas were eligible for
inclusion. After informed consent was obtained, the women were alternately allocated to receive umbilical vein
injection of either 800 mcg misoprostol dissolved in 20 mL of normal saline (misoprostol group) or 20 mL of normal
saline only (saline group). The women were blinded to the group allocation, but the investigator who administered
the injection was not. The trial was registered by the Research Ethics Committee of Hawler Medical University.
Results: After umbilical vein injection, delivery of the placenta occurred in 91.3% of women in the misoprostol
group and 69.5% of women in the saline group, which was not a significant difference between the two groups.
The median vaginal blood loss from the time of injection until delivery of the placenta was significantly less in the
misoprostol group (100 mL) than in the saline group (210 mL) (p value < 0.001).
Conclusion: Umbilical vein injection of misoprostol is an effective treatment for retained placenta, and reduces the
volume of vaginal blood loss with few adverse effects.
Clinical Trial Registration: Current Controlled Trial HMU: N252.1.2011
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Definitions and maternal complications of retained
placenta
No consensus exists regarding the normal length of the
third stage of labour, or the time at which the placenta
should be termed “retained” and intervention should be
started [1].* Correspondence: shahla_alaf@yahoo.com
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reproduction in any medium, provided the orThe intrapartum guidelines published by the National
Institute for Health and Clinical Excellence suggest
intervention when the placenta has not been delivered
within 30 minutes after birth with active management of
the third stage of labour, or within 60 minutes after birth
with physiological management of the third stage of
labour [2].
Complications of RP include shock, postpartum hae-
morrhage, puerperal sepsis, and uterine subinvolution;
which may result in the patient requiring hysterectomy [3].tral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cally that retroplacental myometrial contraction is ne-
cessary to produce the shearing forces to the interface
between the placenta and the myometrium that result in
detachment of the placenta [4].
The current standard of management for RP is manual
removal of the placenta (MROP), which usually requires
general or regional anaesthesia at a hospital. MROP is
an invasive procedure that may lead to serious complica-
tions such as haemorrhage, infection, and genital tract
trauma. A simple and safe treatment for RP that can be
administered at the location of the birth and reduces the
need for MROP could be of major benefit to women
worldwide [5].
Administration of uterotonic drugs via the umbilical
vein
The World Health Organization recommends umbilical
vein injection of a uterotonic drug as the first line of
treatment for RP. However, this treatment is not rou-
tinely used, probably because of lack of a large random-
ized controlled trial, and uncertainties regarding optimal
drug and dosage regimens [6]. A Cochrane collaboration
review found that umbilical vein injection of oxytocin is
not effective for the treatment of RP [7]. A double-blind,
placebo-controlled trial including women in the UK,
Uganda, and Pakistan reported that umbilical vein injec-
tion of oxytocin had no clinically significant effect on
the need for MROP [8].
Study justification
All women should have access to simple and non inva-
sive treatment for RP, whether delivering in a well-
equipped hospital or a low-resource setting. To our
knowledge, this is the first study of the effectiveness of
umbilical vein injection of misoprostol for the treatment
of RP to be conducted at a large maternity hospital. The
Maternity Teaching Hospital is the only public hospital
in Erbil City that manages high-risk pregnancies and de-
liveries. Most local women who develop complications
after giving birth at home are treated at this hospital.
The results of preliminary published trials suggest that
administration of prostaglandins such as misoprostol
may result in delivery of the placenta and reduced vo-
lume of blood loss in women with RP. This study evalu-
ated the effectiveness of umbilical vein injection of
misoprostol dissolved in normal saline versus normal
saline only for the treatment of RP.
Aims
The aims of this study were: (1) to determine whether
umbilical vein injection of misoprostol for the treatment
of RP reduces the need for MROP, and (2) to compare
the volume of vaginal blood loss between women withRP who received umbilical vein injection of misoprostol
and those who received normal saline only.
Hypothesis
The primary hypothesis was that umbilical vein injection
of misoprostol in women with RP despite active manage-
ment of labour reduces the need for MROP under gen-
eral anaesthesia. The secondary hypothesis was that
umbilical vein injection of misoprostol in women with
RP reduces the volume of vaginal blood loss.
Methods
Design and setting
This was a hospital-based, placebo-controlled clinical
trial conducted at the Maternity Teaching Hospital in
Erbil City, Northern Iraq from April 2011 to February
2012, including data collection and entering, follow-up
of women, data analysis, and writing of the manuscript.
The Maternity Teaching Hospital is the only public
maternity hospital in Erbil. This hospital provides
obstetric services including management of high-risk
pregnancies, medical terminations of pregnancy, and
management of high-risk deliveries including caesarean
deliveries. The hospital serves the entire population of
the Erbil governorate, and is equipped to cope with emer-
gency procedures 24 hours a day. The Directorate of
Health in Erbil City reported 22,387 deliveries at the hos-
pital during 2008, with an institutional delivery rate of
53.6%.
Inclusion and exclusion criteria
All women with a singleton pregnancy who delivered vagi-
nally after at least 28 weeks of gestation and had a pro-
longed third stage of labour (more than 30 minutes)
despite active management (intramuscular administration
of 5 IU oxytocin and controlled cord traction) were con-
sidered to have RP, and were eligible for inclusion in the
study unless they had significant bleeding. The exclusion
criteria were: multiple pregnancies, previous caesarean de-
livery, haemodynamic instability, severe anaemia (haemo-
globin concentration <8 g/dL), chorioamnionitis, and
refusal of consent for inclusion (Figure 1).
Enrolment, sample size, and group allocation
Routine management at the Maternity Teaching Hospital
includes active management of the third stage of labour.
Eligible women were identified when the placenta was
not delivered within 30 minutes after delivery of the
infant.
Informed consent was obtained from all subjects after
explanation of the study protocol. The study was ap-
proved and registered by the Research Ethics Committee
and Scientific Committee of the College of Medicine,
Hawler Medical University (N252.1.2011).
Figure 1 Flowchart for trial entry. Abbreviations: AMTSL active management of the third stage of labour, RP retained placenta, MROP manual
removal of placenta, UVI umbilical vein injection.
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misoprostol dissolved in 20 mL of normal saline and the
other containing 20 mL of normal saline only.
Women were alternately allocated to receive umbilical
vein injection of either misoprostol in normal saline
(misoprostol group) or normal saline only (saline group).
The women were blinded to the group allocation, but the
investigator who administered the injection was not. Data
were collected using a specially designed questionnaire,
including the obstetric history, general examinationfindings, vital signs, obstetric and vaginal examination
findings, and haemoglobin concentration.
Umbilical vein injection technique
Umbilical vein injection was performed according to the
Piping’s method, as follows. The cord was cut, and a size
10 paediatric nasogastric tube was advanced into the
umbilical vein. If resistance was felt, the catheter was
retracted 1–2 cm and then advanced further if possible.
If the catheter could not be advanced further without
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catheter at that time. If the majority of the catheter was
inserted before resistance was felt, indicating that it had
reached the placenta, the catheter was retracted 3–4 cm
to ensure that the tip was in the umbilical vein and not
in a placental vessel, before injection [9].
The prepared syringes contained either 800 mcg miso-
prostol (four Misotac® 200 mcg tablets) dissolved in
20 mL of normal saline or 20 mL of normal saline only.
The cord was occluded by finger pressure around the
catheter during injection, and was clamped with the
catheter still in position after injection. If spontaneous
delivery of the placenta did not occur, delivery by gentle
cord traction was attempted at 15 and 30 minutes after
injection. The time from umbilical vein injection to de-
livery of the placenta was recorded. Delivery of the pla-
centa was assessed by clinical signs of placental
separation and expulsion, as described by Rogers et al.
[10]. The same procedures were followed in both treat-
ment arms.
If placental delivery failed to occur within 30 minutes
after the injection, or significant bleeding occurred,
MROP was performed under general anaesthesia. The
time and method of placental delivery (spontaneous by
controlled cord traction or MROP) were recorded.
The volume of blood loss from the time of umbilical
vein injection to delivery of the placenta was measured
by placing a pad under the patient's buttocks. The pad
weighed 45 g before use, and was weighed after delivery
of the placenta using a dedicated electronic scale (up to
5 kg). The blood loss was recorded in mL (1 g =1 mL)
[11].
Adverse effects after misoprostol administration such
as shivering, fever, dizziness, vomiting, flushes, nausea,
abdominal pain, and headache were recorded.Follow-up
All women in both treatment arms were followed up for
24 hours postpartum. Vital signs (blood pressure, pulse
rate, temperature, and respiratory rate), uterine fundal
height, abnormal vaginal bleeding, and abdominal pain
were recorded. Tonics, analgesics, and antibiotics were
prescribed before discharge if needed, according to the
local hospital guidelines.Statistical analysis
All data were analysed using the Statistical Package for
Social Sciences (SPSS), version 18. Proportions were
compared between groups using the χ2 test. Mean values
were compared using the student’s T-test. Mann–
Whitney test was used to determine the median of
blood loss vaginally. A P value of ≤ 0.05 was consi-
dered statistically significant.Results
RP is a relatively rare condition that may occur without
any risk factors. Fifty women were diagnosed with RP
during the study period, of which 46 met the criteria for
inclusion in the study. Twenty-three women were allo-
cated to each of the misoprostol and saline groups. In
one woman in the misoprostol group, the cord detached
from the placenta after injection.
Patient characteristics
There were no significant differences between the miso-
prostol and saline groups in terms of mean age, parity,
or gestational age. There were also no significant diffe-
rences between the two groups in terms of risk factors
for RP including history of dilatation and curettage, pre-
term labour, and history of RP (Table 1).
Outcomes after umbilical vein injection
After umbilical vein injection, the placenta was delivered
in 21 of the 23 women in the misoprostol group, and in
16 of the 23 women in the saline group, which was not a
significant difference between the two groups (Table 2).
The median volume of blood loss from the time of
umbilical vein injection until delivery of the placenta
was significantly less in the misoprostol group (100 mL)
than in the saline group (210 mL) using Mann–Whitney
test.The range of vaginal blood loss vaginally was 30-
75 ml while the rang time to delivery using controlled
cord traction was (5-23 minutes) in the misoprostol
group versus (7-30 minutes) in the normal saline group
(Table 2).
The mean time from injection until delivery of the pla-
centa was 12.61 ± 6.479 minutes in the misoprostol
group and 13.17 ± 10.152 minutes in the saline group
(P = 0.823).
Adverse effects after umbilical vein injection of
misoprostol
One of the 23 women who received misoprostol deve-
loped shivering that was attributed to misoprostol
injection.
Discussion
Delivery of the placenta
The placenta was delivered after umbilical vein injection
in 91.3% of the women who received misoprostol. The
Cochrane review of umbilical vein injection for the treat-
ment of RP found that injection of a prostaglandin solu-
tion resulted in a significant reduction in the rate of
MROP compared with injection of saline solution, but did
not result in differences in the volume of vaginal blood
loss or adverse effects. However, the review was based on
only two small trials including a total of 51 women, and
both trials had low methodological quality [7].
Table 1 Demographic characteristics and risk factors for retained placenta
Characters and risk factors Groups(n = 23, in each group) Mean ± SD P
Age (years) Mesoprostol group 24.52 ± 5.169 *.374
Normal saline group 25.83 ± 4.668
Parity Mesoprostol group 1.30 ± 1.222 *.37
Normal saline group 2.00 ± 0.953
G. age (weeks) Mesoprostol group 37.22 ± 2.876 *.559
Normal saline group 37.61 ± 1.373
History of dilatation and curettage Mesoprostol group 4(17.4%) **1.000
Normal saline group 5(21.7%)
History of preterm labour Mesoprostol group 4(17.4%) **0.347
Normal saline group 1(4.3%)
History of retained placenta Mesoprostol group 1(4.3%) **1.00
Normal saline group 0(0%)
*T-Test, **χ2 test.
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interacts with specific receptors on myometrial cells, ini-
tiating a cascade of events including a change in calcium
concentration that initiates myometrial contraction, and
softening of the cervix, leading to expulsion of the uter-
ine contents [12].
Umbilical vein injection of misoprostol may result in
local action of misoprostol at the base of the placenta.
The results of this study are comparable with those of a
previous study that concluded that misoprostol was an
effective treatment for RP compared with normal saline
[4]. However, there was no significant difference in the
rate of delivery of the placenta between the misoprostol
and saline groups in this study, which may be due to the
small sample size.
Volume of blood loss
There was a significant difference in the median volume
of vaginal blood loss after umbilical vein injection between
the misoprostol group and the saline group. This finding
differed from those of Bider et al. [13], who reported a
mean volume of blood loss of 210 mL in the prostaglandin
group and 231 mL in the saline group (p = 0.7). This dif-
ference may be due to the smaller sample size of their
study (n = 17) and the different uterotonic drug used
(a prostaglandin F2 alpha analogue).Table 2 Comparisons of outcomes between the misoprostol a





CCT: controlled cord traction.
*Fisher’s exact test, +Mann–Whitney test.Time to delivery of the placenta
The mean time from umbilical vein injection until separ-
ation of the placenta was shorter in the misoprostol
group (13.63 ± 5.29 minutes) than in the saline group
(18.93 ± 5.89 minutes), but this was not a significant dif-
ference between the two groups. Rogers et al. reported
no significant difference in the time to delivery of the
placenta between the misoprostol and normal saline
groups [14].
Harara et al. reported that the time to delivery of the
placenta was significantly shorter in the misoprostol
group (7.0 ± 2.2 minutes). This may be because they
compared misoprostol with two other uterotonic drugs
(ergometrine and oxytocin) rather than with normal sa-
line as in the current study [8].
Adverse effects of misoprostol
Only 1 of the 23 women who received misoprostol deve-
loped shivering. Bider et al. reported that 1 of 10 women
experienced adverse effects (fever and shivering) after
administration of a prostaglandin F2 alpha analogue [14].
Limitations
Although this study had significant findings in terms of
delivery of the placenta after umbilical vein injection, it
had some limitations. The sample size was small becausend saline groups
up(n = 23) Outcome
) Need for manual removal of placenta
Median of blood loss vaginally
Range of blood loss vaginally (ml)
Range time for placental separation after CCT(mint)
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als conducted over longer periods of time will be re-
quired to obtain definitive results. This study was also
prone to assessment bias, because the investigator who
administered the umbilical vein injection was aware of
the group allocation. However, the women were alter-
nately allocated to the two groups, and were not previ-
ously known to the investigators.
Conclusion
Umbilical vein injection of misoprostol dissolved in nor-
mal saline resulted in a reduced rate of MROP under
general anaesthesia compared with injection of normal
saline only.
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